Research presented at the 2017 American College of Rheumatology Annual Meeting found that patients with rheumatoid arthritis and higher body mass index were less likely to achieve remission and more likely to face higher rates of disability.
Body mass index (BMI) scores can impact disease activity in patients with rheumatoid arthritis (RA). New research presented at the 2017 American College of Rheumatology's Annual Meeting in San Diego, California, explored associations between BMI and disease remission or low disease activity and functional ability in RA.
Researchers determined that patients with RA and higher BMI have lower rates of remission and higher rates of disability. They suggest that weight screening and management should be a part of RA management.
“Obesity is increasing in prevalence and represents a global health concern. It has been implicated as a risk factor for developing RA, and is an increasingly prevalent comorbidity seen on first presentation of RA,” Elena Nikiphorou, MD, a researcher in the Academic Rheumatology Department at King’s College, London, and a lead author of the study, said in a statement. “There is growing recognition that the inflammatory states mediated by obesity and those by inflammatory rheumatic diseases share common pathways.”
RA causes pain, stiffness, swelling, and limitation in multiple joints and inflammation can develop in other organs. Previous research has linked inflammation, obesity, and joint dysfunction, and the purpose of this study was to more clearly define how these conditions are associated with clinical disease activity and functional disability for patients with RA.
The researchers used data from the Early RA Study (ERAS) and the Early RA Network (ERAN), both of which were multicenter RA inception cohorts in the United Kingdom. There was a total of 1465 patients with a median follow-up of 10 years and a maximum follow-up of 25 years in ERAS, and a total of 1236 patients with a median follow-up of 6 years and a maximum follow-up of 10 years in ERAN.
The study found that 37.2% of RA patients were overweight and 21.3% were obese. BMI increased over 5 years for patients in both the ERAS and ERAN groups. Adjusted for age, sex, and year of recruitment, a higher BMI was associated with a reduced likelihood of patients with RA achieving low disease activity—based on scores of Remission-DAS and Low-DAS—and increased odds of disability by 63%.
“Our study’s findings demonstrate the increasing prevalence of obesity in RA patients and its negative consequences on disease activity, achieving a treat-to-target low disease activity goal and good functional outcomes,” said Nikiphorou. “Obesity is potentially a reversible comorbidity and successfully treating it can contribute to better disease activity and functional outcomes. Based on our data, there is a strong argument to include obesity screening and management as a central part of all treatment plans for RA patients.”
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study
September 28th 2024A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford University School of Medicine, gave an overview of patient-reported outcomes (PROs) in the VOLTAIRE-RA trial.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.